Search

Your search keyword '"Ahn, Linda"' showing total 42 results
Start Over Author "Ahn, Linda"
42 results on '"Ahn, Linda"'

5. Supplemental Figure 1 from Brief Report: Combination of Osimertinib and Dacomitinib to Mitigate Primary and Acquired Resistance in EGFR-Mutant Lung Adenocarcinomas

Author

Elkrief, Arielle, primary, Makhnin, Alex, primary, Moses, Khadeja A., primary, Ahn, Linda S., primary, Preeshagul, Isabel R., primary, Iqbal, Afsheen N., primary, Hayes, Sara A., primary, Plodkowski, Andrew J., primary, Paik, Paul K., primary, Ladanyi, Marc, primary, Kris, Mark G., primary, Riely, Gregory J., primary, Michor, Franziska, primary, and Yu, Helena A., primary

Published
2023
Full Text
View/download PDF

6. Supplemental Figure 4 from Brief Report: Combination of Osimertinib and Dacomitinib to Mitigate Primary and Acquired Resistance in EGFR-Mutant Lung Adenocarcinomas

Author

Elkrief, Arielle, primary, Makhnin, Alex, primary, Moses, Khadeja A., primary, Ahn, Linda S., primary, Preeshagul, Isabel R., primary, Iqbal, Afsheen N., primary, Hayes, Sara A., primary, Plodkowski, Andrew J., primary, Paik, Paul K., primary, Ladanyi, Marc, primary, Kris, Mark G., primary, Riely, Gregory J., primary, Michor, Franziska, primary, and Yu, Helena A., primary

Published
2023
Full Text
View/download PDF

7. Data from Brief Report: Combination of Osimertinib and Dacomitinib to Mitigate Primary and Acquired Resistance in EGFR-Mutant Lung Adenocarcinomas

Author

Elkrief, Arielle, primary, Makhnin, Alex, primary, Moses, Khadeja A., primary, Ahn, Linda S., primary, Preeshagul, Isabel R., primary, Iqbal, Afsheen N., primary, Hayes, Sara A., primary, Plodkowski, Andrew J., primary, Paik, Paul K., primary, Ladanyi, Marc, primary, Kris, Mark G., primary, Riely, Gregory J., primary, Michor, Franziska, primary, and Yu, Helena A., primary

Published
2023
Full Text
View/download PDF

8. Supplementary Table 1 from Brief Report: Combination of Osimertinib and Dacomitinib to Mitigate Primary and Acquired Resistance in EGFR-Mutant Lung Adenocarcinomas

Author

Elkrief, Arielle, primary, Makhnin, Alex, primary, Moses, Khadeja A., primary, Ahn, Linda S., primary, Preeshagul, Isabel R., primary, Iqbal, Afsheen N., primary, Hayes, Sara A., primary, Plodkowski, Andrew J., primary, Paik, Paul K., primary, Ladanyi, Marc, primary, Kris, Mark G., primary, Riely, Gregory J., primary, Michor, Franziska, primary, and Yu, Helena A., primary

Published
2023
Full Text
View/download PDF

9. Supplemental Figure 3 from Brief Report: Combination of Osimertinib and Dacomitinib to Mitigate Primary and Acquired Resistance in EGFR-Mutant Lung Adenocarcinomas

Author

Elkrief, Arielle, primary, Makhnin, Alex, primary, Moses, Khadeja A., primary, Ahn, Linda S., primary, Preeshagul, Isabel R., primary, Iqbal, Afsheen N., primary, Hayes, Sara A., primary, Plodkowski, Andrew J., primary, Paik, Paul K., primary, Ladanyi, Marc, primary, Kris, Mark G., primary, Riely, Gregory J., primary, Michor, Franziska, primary, and Yu, Helena A., primary

Published
2023
Full Text
View/download PDF

10. Supplemental Figure 2 from Brief Report: Combination of Osimertinib and Dacomitinib to Mitigate Primary and Acquired Resistance in EGFR-Mutant Lung Adenocarcinomas

Author

Elkrief, Arielle, primary, Makhnin, Alex, primary, Moses, Khadeja A., primary, Ahn, Linda S., primary, Preeshagul, Isabel R., primary, Iqbal, Afsheen N., primary, Hayes, Sara A., primary, Plodkowski, Andrew J., primary, Paik, Paul K., primary, Ladanyi, Marc, primary, Kris, Mark G., primary, Riely, Gregory J., primary, Michor, Franziska, primary, and Yu, Helena A., primary

Published
2023
Full Text
View/download PDF

11. Figure S2 from A Phase II Trial of Albumin-Bound Paclitaxel and Gemcitabine in Patients with Newly Diagnosed Stage IV Squamous Cell Lung Cancers

Author

Paik, Paul K., primary, Kim, Rachel K., primary, Ahn, Linda, primary, Plodkowski, Andrew J., primary, Ni, Ai, primary, Donoghue, Mark T.A., primary, Jonsson, Philip, primary, Villalona-Calero, Miguel, primary, Ng, Kenneth, primary, McFarland, Daniel, primary, Fiore, John J., primary, Iqbal, Afsheen, primary, Eng, Juliana, primary, Kris, Mark G., primary, and Rudin, Charles M., primary

Published
2023
Full Text
View/download PDF

12. Supplementary Tables from A Phase II Trial of Albumin-Bound Paclitaxel and Gemcitabine in Patients with Newly Diagnosed Stage IV Squamous Cell Lung Cancers

Author

Paik, Paul K., primary, Kim, Rachel K., primary, Ahn, Linda, primary, Plodkowski, Andrew J., primary, Ni, Ai, primary, Donoghue, Mark T.A., primary, Jonsson, Philip, primary, Villalona-Calero, Miguel, primary, Ng, Kenneth, primary, McFarland, Daniel, primary, Fiore, John J., primary, Iqbal, Afsheen, primary, Eng, Juliana, primary, Kris, Mark G., primary, and Rudin, Charles M., primary

Published
2023
Full Text
View/download PDF

13. Brief Report: Combination of Osimertinib and Dacomitinib to Mitigate Primary and Acquired Resistance in EGFR-Mutant Lung Adenocarcinomas

Author

Elkrief, Arielle, primary, Makhnin, Alex, additional, Moses, Khadeja A., additional, Ahn, Linda S., additional, Preeshagul, Isabel R., additional, Iqbal, Afsheen N., additional, Hayes, Sara A., additional, Plodkowski, Andrew J., additional, Paik, Paul K., additional, Ladanyi, Marc, additional, Kris, Mark G., additional, Riely, Gregory J., additional, Michor, Franziska, additional, and Yu, Helena A., additional

Published
2023
Full Text
View/download PDF

14. Tepotinib: Guidance for oncology nurses on management of adverse events in patients with MET exon 14 skipping non-small-cell lung cancer

Author

Ahn, Linda, Alexander, Terri, Vlassak, Soetkin, Berghoff, Karin, and Lemmens, Liesbeth

Subjects
Pyridazines, Lung Neoplasms, Pyrimidines, Piperidines, Carcinoma, Non-Small-Cell Lung, Creatinine, Humans, Exons, Article
Abstract

BACKGROUND: Tepotinib, a highly selective, oral, once-daily MET inhibitor, has recently been approved for treatment of metastatic MET exon 14 skipping non-small cell lung cancer. OBJECTIVES: This article provides nurse-specific recommendations for identification and management of tepotinib adverse events (AEs). METHODS: Guidance on monitoring and proactive/reactive AE management was developed based on published literature and real-world nursing experience. Case studies of VISION trial participants were summarized to illustrate key principles. FINDINGS: Tepotinib AEs are generally mild/moderate, manageable, and mostly include peripheral edema, hypoalbuminemia, nausea, diarrhea, and creatinine increase. Alongside supportive care, tepotinib interruption and dose reduction is recommended for Grade 3 AEs. Peripheral edema may be easier to manage if recognized early, before it becomes more established and difficult to treat. Proactive monitoring is therefore crucial and should include regular measurement of body weight and limb circumference, and limb inspection for swelling or skin erosion. Treatment interruption (including frequent, short treatment holidays) should be considered early for peripheral edema. Gastrointestinal AEs are typically transient, and may be limited by administration with food and effectively managed with antidiarrheals/antiemetics. Through effective patient education, proactive monitoring, and coordination of multidisciplinary teamworking, nurses play a key role in managing the most common tepotinib AEs.

Published
2022

15. Targeting NFE2L2/KEAP1 Mutations in Advanced NSCLC With the TORC1/2 Inhibitor TAK-228

Author

Paik, Paul K., primary, Fan, Pang-Dian, additional, Qeriqi, Besnik, additional, Namakydoust, Azadeh, additional, Daly, Bobby, additional, Ahn, Linda, additional, Kim, Rachel, additional, Plodkowski, Andrew, additional, Ni, Ai, additional, Chang, Jason, additional, Fanaroff, Rachel, additional, Ladanyi, Marc, additional, de Stanchina, Elisa, additional, and Rudin, Charles M., additional

Published
2022
Full Text
View/download PDF

18. Quality of Life

Author

Cajulis, Corazon B., primary, Ahn, Linda, additional, Deboer, Colleen, additional, and O'dea, Denise, additional

Published
2016
Full Text
View/download PDF

20. Targeting NFE2L2/KEAP1Mutations in Advanced NSCLC With the TORC1/2 Inhibitor TAK-228

Author

Paik, Paul K., Fan, Pang-Dian, Qeriqi, Besnik, Namakydoust, Azadeh, Daly, Bobby, Ahn, Linda, Kim, Rachel, Plodkowski, Andrew, Ni, Ai, Chang, Jason, Fanaroff, Rachel, Ladanyi, Marc, de Stanchina, Elisa, and Rudin, Charles M.

Abstract

Increased insight into the mutational landscape of squamous cell lung cancers (LUSCs) in the past decade has not translated into effective targeted therapies for patients with this disease. NRF2, encoded by NFE2L2, and its upstream regulator, KEAP1, control key aspects of redox balance and are frequently mutated in NSCLCs.

Published
2023
Full Text
View/download PDF

21. Tepotinib: Management of Adverse Events in Patients With MET Exon 14 Skipping Non-Small Cell Lung Cancer.

Author

Ahn, Linda, Alexander, Terri, Vlassak, Soetkin, Berghoff, Karin, and Lemmens, Liesbeth

Subjects
*PREVENTION of drug side effects, *LUNG cancer, *GENETIC mutation, *PLEURAL effusions, *ANTINEOPLASTIC agents, *GASTROINTESTINAL diseases, *INTERSTITIAL lung diseases, *PROTEIN-tyrosine kinase inhibitors, *VENOUS thrombosis, *NURSES, *DRUG monitoring, *CELL proliferation, *QUALITY of life, *PATIENT education, *AMINOTRANSFERASES, *EDEMA, *BLOOD protein disorders, *CREATININE
Abstract

BACKGROUND: Tepotinib, a highly selective, oral, once-daily MET inhibitor, has been approved for treatment of metastatic MET exon 14 skipping nonsmall cell lung cancer. OBJECTIVES: This article provides nurse-specific recommendations for identification and management of tepotinib adverse events (AEs). METHODS: Guidance on monitoring and proactive/reactive AE management was developed based on published literature and real-world nursing experience. Case studies of VISION trial participants were summarized to illustrate key principles. FINDINGS: Tepotinib AEs are generally mild to moderate and manageable, and can include peripheral edema, hypoalbuminemia, nausea, diarrhea, and creatinine increase. Alongside supportive care, tepotinib interruption and dose reduction is recommended for grade 3 AEs. For peripheral edema, proactive monitoring is crucial, and treatment interruption (including frequent, short treatment holidays) should be considered early. Nursing management of tepotinib AEs includes proactive monitoring, patient education, and interprofessional team coordination. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

22. Effect of Osimertinib and Bevacizumab on Progression-Free Survival for Patients With Metastatic EGFR-Mutant Lung Cancers

Author

Yu, Helena A., primary, Schoenfeld, Adam J., additional, Makhnin, Alex, additional, Kim, Rachel, additional, Rizvi, Hira, additional, Tsui, Dana, additional, Falcon, Christina, additional, Houck-Loomis, Brian, additional, Meng, Fanli, additional, Yang, Julie Li, additional, Tobi, Yosef, additional, Heller, Glenn, additional, Ahn, Linda, additional, Hayes, Sara A., additional, Young, Robert J., additional, Arcila, Maria E., additional, Berger, Michael, additional, Chaft, Jamie E., additional, Ladanyi, Marc, additional, Riely, Gregory J., additional, and Kris, Mark G., additional

Published
2020
Full Text
View/download PDF

24. A Phase II Trial of Albumin-Bound Paclitaxel and Gemcitabine in Patients with Newly Diagnosed Stage IV Squamous Cell Lung Cancers

Author

Paik, Paul K., primary, Kim, Rachel K., additional, Ahn, Linda, additional, Plodkowski, Andrew J., additional, Ni, Ai, additional, Donoghue, Mark T.A., additional, Jonsson, Philip, additional, Villalona-Calero, Miguel, additional, Ng, Kenneth, additional, McFarland, Daniel, additional, Fiore, John J., additional, Iqbal, Afsheen, additional, Eng, Juliana, additional, Kris, Mark G., additional, and Rudin, Charles M., additional

Published
2020
Full Text
View/download PDF

25. Clinical outcomes of systemic therapy for patients with deep fibromatosis (desmoid tumor)

Author

Pires de Camargo, Veridiana, Keohan, Mary L., D'Adamo, David R., Antonescu, Cristina R., Brennan, Murray F., Singer, Samuel, Ahn, Linda S., and Maki, Robert G.

Subjects
Fibromas -- Care and treatment, Fibromas -- Patient outcomes, Fibromas -- Research, Anthracyclines -- Dosage and administration, Anthracyclines -- Research, Health
Published
2010

28. Exceptional responders with invasive mucinous adenocarcinomas: a phase 2 trial of bortezomib in patients with KRAS G12D-mutant lung cancers

Author

Drilon, Alexander, primary, Schoenfeld, Adam J., additional, Arbour, Kathryn C., additional, Litvak, Anna, additional, Ni, Ai, additional, Montecalvo, Joseph, additional, Yu, Helena A., additional, Panora, Elizabeth, additional, Ahn, Linda, additional, Kennedy, Maureen, additional, Haughney-Siller, Anne, additional, Miller, Vincent, additional, Ginsberg, Michelle, additional, Ladanyi, Marc, additional, Arcila, Maria, additional, Rekhtman, Natasha, additional, Kris, Mark G., additional, and Riely, Gregory J., additional

Published
2019
Full Text
View/download PDF

29. Twice Weekly Pulse and Daily Continuous Dose Erlotinib as Initial Treatment for Patients with EGFR-Mutant Lung Cancers and Brain Metastases

Author

Arbour, Kathryn C., Kris, Mark G., Riely, Gregory J., Ni, Ai, Beal, Kathryn, Daras, Mariza, Hayes, Sara A., Young, Robert J., Rodriguez, Christopher R, Ahn, Linda, Pao, William, and Yu, Helena A.

Subjects
Aged, 80 and over, Male, Lung Neoplasms, Brain Neoplasms, Adenocarcinoma, Middle Aged, Article, Disease-Free Survival, Tumor Burden, ErbB Receptors, Erlotinib Hydrochloride, Treatment Outcome, Mutation, Humans, Female, Cranial Irradiation, Protein Kinase Inhibitors, Response Evaluation Criteria in Solid Tumors, Aged
Abstract

In a phase 1 study of pulse/continuous-dose erlotinib, no patient had disease progression in the central nervous system (CNS). This expansion cohort of the phase 1 study tested the same regimen in a cohort of individuals with epidermal growth factor receptor (EGFR)-mutant lung cancers with untreated brain metastases.Patients had not received EGFR tyrosine kinase inhibitors or radiation for brain metastases. All received 1200 mg of erlotinib on days 1 and 2 and 50 mg on days 3 to 7 weekly. The primary endpoints were the overall and CNS response rates (according to version 1.1 of the Response Evaluation Criteria in Solid Tumors).Between May 2015 and August 2016, 19 patients were enrolled. Forty-two percent of the patients had target brain lesions, and the median size of the target brain lesions was 13 mm. Overall, 14 patients (74%; 95% confidence interval [CI], 51%-89%) had partial responses. The response rate in brain metastases was 75%. The overall median progression-free survival was 10 months (95% CI, 7 months to not reached). Only 3 patients (16%) had CNS progression. To date, 4 patients required CNS radiation at some time during their course. The adverse events (any grade) seen in 10% or more of the patients were rash, diarrhea, nausea, an increase in alanine aminotransferase, and fatigue.Pulse/continuous-dose erlotinib produced a 74% overall response rate and a 75% response rate in brain metastases in patients with EGFR-mutant lung cancers and untreated brain metastases. CNS control persisted even after progression elsewhere. Although this regimen did not improve progression-free survival or delay the emergence of EGFR T790M, it prevented progression in the brain and could be useful in situations in which CNS control is critical. Cancer 2018;124:105-9. © 2017 American Cancer Society.

Published
2017

30. A Phase II Trial of Sorafenib and Dacarbazine for Leiomyosarcoma, Synovial Sarcoma, and Malignant Peripheral Nerve Sheath Tumors

Author

D'Adamo, David R., primary, Dickson, Mark A., additional, Keohan, Mary L., additional, Carvajal, Richard D., additional, Hensley, Martee L., additional, Hirst, Catherine M., additional, Ezeoke, Marietta O., additional, Ahn, Linda, additional, Qin, Li-Xuan, additional, Antonescu, Cristina R., additional, Lefkowitz, Robert A., additional, Maki, Robert G., additional, Schwartz, Gary K., additional, and Tap, William D., additional

Published
2018
Full Text
View/download PDF

31. A phase II trial of albumin-bound paclitaxel and gemcitabine in patients with newly diagnosed PD-L1 IHC low/unknown stage IV squamous cell lung cancers.

Author

Paik, Paul K., primary, Srikakulum, Aparajita, additional, Ahn, Linda Su Hyun, additional, Plodkowski, Andrew J., additional, Ng, Kenneth K., additional, McFarland, Daniel, additional, Fiore, John Joseph, additional, Iqbal, Afsheen, additional, Eng, Juliana, additional, and Rudin, Charles M., additional

Published
2018
Full Text
View/download PDF

33. Twice weekly pulse and daily continuous-dose erlotinib as initial treatment for patients with epidermal growth factor receptor-mutant lung cancers and brain metastases

Author

Arbour, Kathryn C., primary, Kris, Mark G., additional, Riely, Gregory J., additional, Ni, Ai, additional, Beal, Kathryn, additional, Daras, Mariza, additional, Hayes, Sara A., additional, Young, Robert J., additional, Rodriguez, Christopher R., additional, Ahn, Linda, additional, Pao, William, additional, and Yu, Helena A., additional

Published
2017
Full Text
View/download PDF

34. A Phase II Trial of Sorafenib and Dacarbazine for Leiomyosarcoma, Synovial Sarcoma, and Malignant Peripheral Nerve Sheath Tumors.

Author

D'Adamo, David R., Dickson, Mark A., Keohan, Mary L., Carvajal, Richard D., Hensley, Martee L., Hirst, Catherine M., Ezeoke, Marietta O., Ahn, Linda, Qin, Li‐Xuan, Antonescu, Cristina R., Lefkowitz, Robert A., Maki, Robert G., Schwartz, Gary K., and Tap, William D.

Subjects
BONE marrow, BONE marrow cancer, CLINICAL trials, DRUG toxicity, FEBRILE neutropenia, HEMATOLOGY, INTRAVENOUS therapy, KIDNEY tumors, LIVER tumors, NERVOUS system tumors, ORAL drug administration, SARCOMA, TREATMENT effectiveness, LEIOMYOSARCOMA, DACARBAZINE, SORAFENIB, THERAPEUTICS
Abstract

Background: Sorafenib and dacarbazine have low single‐agent response rates in metastatic sarcomas. As angiogenesis inhibitors can enhance the efficacy of chemotherapy, we investigated the combination of sorafenib and dacarbazine in select sarcoma subtypes. Materials and Methods: Patients with leiomyosarcoma (LMS), synovial sarcoma (SS), or malignant peripheral nerve sheath tumors (MPNST) with up to two previous lines of therapy and adequate hepatic, renal, and marrow function received 3‐week cycles of sorafenib at 400 mg oral twice daily and dacarbazine 1,000 mg/m2 intravenously (later reduced to 850 mg/m2). Patients were evaluated for response every 6 weeks. The primary objective was to determine the disease control rate (DCR) of sorafenib plus dacarbazine in the selected sarcoma subtypes. Results: The study included 37 patients (19 female); median age was 55 years (range 26–87); and histologies included LMS (22), SS (11), and MPNST (4). The DCR was 46% (17/37). Median progression‐free survival was 13.4 weeks. The RECIST response rate was 14% (5/37). The Choi response rate was 51% (19/37). Median overall survival was 13.2 months. Of the first 25 patients, 15 (60%) required dacarbazine dose reductions for hematologic toxicity, with one episode of grade 5 neutropenic fever. After reducing the starting dose of dacarbazine to 850 mg/m2, only 3 of the final 12 (25%) patients required dose reduction. Conclusion: This phase II study met its primary endpoint with an 18‐week DCR of 46%. The clinical activity of dacarbazine plus sorafenib in patients with these diagnoses is modest. Implications for Practice: Metastatic soft tissue sarcomas are a heterogeneous group of relatively rare malignancies. Most patients are treated with cytotoxic chemotherapy or targeted therapy in the form of tyrosine kinase inhibitors. Response rates are relatively low, and there is a need for better therapies. This clinical trial demonstrates that combining a cytotoxic therapy (dacarbazine) with an antiangiogenic small molecule (sorafenib) is feasible and associated with favorable disease‐control rates; however, it also increases the potential for significant toxicity. Sorafenib and dacarbazine have low single agent response rates in metastatic sarcomas. This article reports results of a clinical trial using a combination of sorafenib and dacarbazine in select sarcoma subtypes. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

36. Malignant Peripheral Nerve Sheath Tumors

Author

Farid, Mohamad, primary, Demicco, Elizabeth G., additional, Garcia, Roberto, additional, Ahn, Linda, additional, Merola, Pamela R., additional, Cioffi, Angela, additional, and Maki, Robert G., additional

Published
2014
Full Text
View/download PDF

38. Activity of Sorafenib against Desmoid Tumor/Deep Fibromatosis

Author

Gounder, Mrinal M., primary, Lefkowitz, Robert A., additional, Keohan, Mary Louise, additional, D'Adamo, David R., additional, Hameed, Meera, additional, Antonescu, Cristina R., additional, Singer, Samuel, additional, Stout, Katherine, additional, Ahn, Linda, additional, and Maki, Robert G., additional

Published
2011
Full Text
View/download PDF

42. Exceptional responders with invasive mucinous adenocarcinomas: a phase 2 trial of bortezomib in patients with KRAS G12D-mutant lung cancers.

Author

Drilon A, Schoenfeld AJ, Arbour KC, Litvak A, Ni A, Montecalvo J, Yu HA, Panora E, Ahn L, Kennedy M, Haughney-Siller A, Miller V, Ginsberg M, Ladanyi M, Arcila M, Rekhtman N, Kris MG, and Riely GJ

Subjects
Adenocarcinoma, Mucinous genetics, Adult, Aged, Aged, 80 and over, Antineoplastic Agents adverse effects, Bortezomib adverse effects, Carcinoma, Non-Small-Cell Lung genetics, Female, Humans, Injections, Subcutaneous, Lung Neoplasms genetics, Male, Middle Aged, Mutation, Prospective Studies, Treatment Outcome, Adenocarcinoma, Mucinous drug therapy, Antineoplastic Agents administration & dosage, Bortezomib administration & dosage, Carcinoma, Non-Small-Cell Lung drug therapy, Lung Neoplasms drug therapy, Proto-Oncogene Proteins p21(ras) genetics
Abstract

KRAS G12D-mutant/p53-deficient non-small-cell lung cancer (NSCLC) models are dependent on the NF-κB pathway that can be down-regulated by the proteasome inhibitor bortezomib. Two exceptional responders were observed on prior clinical trials of bortezomib, both of whom had KRAS G12D-mutant NSCLC, prompting the initiation of this single-center phase 2 trial. Patients with advanced KRAS G12D-mutant NSCLC were eligible. Bortezomib was administered at 1.3 mg/m 2 subcutaneously (days 1, 4, 8, 11; 21-d cycle) until progression or unacceptable toxicity. The primary objective was best objective response (RECIST v1.1). Sixteen patients with KRAS G12D-mutant lung adenocarcinomas were treated. Patients had a median pack year smoking history of 4 (range 0-45). A partial response (PR) was observed in one patient (-66% from baseline) and stable disease in five patients on the first stage of this study (overall response rate of 6%, 95% CI: 0.2-30.2), and further patients were not accrued. The median progression-free survival was 1 mo (95% CI: 1-6). The median overall survival was 13 mo (95% CI: 6-NA). The most common treatment-related adverse events were fatigue (38%) and diarrhea (26%). TP53 status did not predict response on exploratory testing. Of note, the patient with a PR had a unique subtype of lung adenocarcinoma-invasive mucinous adenocarcinomas (IMA)-and had rapid clinical improvement and substantial disease regression, which was also previously observed in two other patients with advanced KRAS G12D-mutant lung cancer with IMAs who received bortezomib on separate clinical trials. Exceptional responses to bortezomib can be achieved in KRAS G12D-mutant NSCLCs. KRAS G12D mutation alone, however, is not a robust predictor of response. Further evaluation should only be performed after further elucidation of other factors such as co-occurring alterations and histologic subtype such as IMA that may predict sensitivity to therapy., (© 2019 Drilon et al.; Published by Cold Spring Harbor Laboratory Press.)

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results